Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
$0.50
$0.48
$0.36
$7.31
$7.46M1.9876,300 shsN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$4.72
-8.7%
$5.56
$2.26
$6.79
$281.97M0.23310,187 shs116,571 shs
OncoCyte Co. stock logo
OCX
OncoCyte
$2.47
+1.2%
$2.90
$2.08
$6.20
$20.43M0.847,490 shs15,071 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-1.15%-4.08%-15.66%+7.04%+119.07%
OncoCyte Co. stock logo
OCX
OncoCyte
-0.81%-4.69%-19.74%-22.04%-50.71%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
2.0165 of 5 stars
3.53.00.00.01.72.50.0
OncoCyte Co. stock logo
OCX
OncoCyte
1.7975 of 5 stars
3.32.00.00.02.92.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
3.00
Buy$12.67168.36% Upside
OncoCyte Co. stock logo
OCX
OncoCyte
2.50
Moderate Buy$4.0664.47% Upside

Current Analyst Ratings

Latest AYLA, LYRA, and OCX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$3.60 ➝ $4.25
4/17/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$4.00
4/15/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$5.00
3/25/2024
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
3/22/2024
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
$3.51M2.13N/AN/A$2.45 per share0.21
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$1.56M180.75N/AN/A$1.56 per share3.03
OncoCyte Co. stock logo
OCX
OncoCyte
$1.50M13.62N/AN/A$2.48 per share1.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$62.68M-$1.29N/AN/AN/A-4,023.11%-72.62%-50.90%5/10/2024 (Estimated)
OncoCyte Co. stock logo
OCX
OncoCyte
-$27.78MN/A0.00N/A-1,890.62%-96.30%-41.12%5/9/2024 (Estimated)

Latest AYLA, LYRA, and OCX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$0.33-$0.22+$0.11-$0.22$0.52 million$0.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/AN/AN/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/A
2.28
2.28
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/A
5.35
5.35
OncoCyte Co. stock logo
OCX
OncoCyte
N/A
1.49
1.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
22.10%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
95.62%
OncoCyte Co. stock logo
OCX
OncoCyte
55.35%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
3.60%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
17.42%
OncoCyte Co. stock logo
OCX
OncoCyte
1.94%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
3514.82 million14.29 millionNot Optionable
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
8859.74 million49.34 millionOptionable
OncoCyte Co. stock logo
OCX
OncoCyte
758.27 million8.11 millionNo Data

AYLA, LYRA, and OCX Headlines

SourceHeadline
OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLCOncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC
americanbankingnews.com - April 25 at 5:26 AM
Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial EfficiencyStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency
markets.businessinsider.com - April 24 at 6:06 PM
OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.comOncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com
americanbankingnews.com - April 24 at 2:22 AM
Buffett Grabs More of This Stock, Plus Other Notable Insider BuyingBuffett Grabs More of This Stock, Plus Other Notable Insider Buying
msn.com - April 22 at 12:51 AM
Stephens Reiterates "Equal Weight" Rating for OncoCyte (NASDAQ:OCX)Stephens Reiterates "Equal Weight" Rating for OncoCyte (NASDAQ:OCX)
americanbankingnews.com - April 19 at 5:50 AM
OncoCyte (NASDAQ:OCX) Now Covered by StockNews.comOncoCyte (NASDAQ:OCX) Now Covered by StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Buys 3,390 SharesOncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Buys 3,390 Shares
americanbankingnews.com - April 16 at 6:58 AM
OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of StockOncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of Stock
americanbankingnews.com - April 16 at 5:44 AM
OncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at BenchmarkOncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at Benchmark
americanbankingnews.com - April 16 at 4:50 AM
OncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in StockOncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stock
insidertrades.com - April 16 at 4:46 AM
OncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Buys 2,420,000 Shares of StockOncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Buys 2,420,000 Shares of Stock
americanbankingnews.com - April 16 at 4:18 AM
OncoCyte Corporation (OCX) Q4 2023 Earnings Call TranscriptOncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript
seekingalpha.com - April 13 at 10:47 PM
Q4 2023 OncoCyte Corp Earnings CallQ4 2023 OncoCyte Corp Earnings Call
finance.yahoo.com - April 13 at 1:38 AM
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 12 at 12:00 PM
Top 3 Health Care Stocks That May Collapse In Q2Top 3 Health Care Stocks That May Collapse In Q2
msn.com - April 12 at 10:36 AM
OncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
finanznachrichten.de - April 12 at 10:10 AM
S&P Futures Tick Lower as Investors Digest Big Bank EarningsS&P Futures Tick Lower as Investors Digest Big Bank Earnings
msn.com - April 12 at 10:10 AM
S&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank EarningsS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earnings
msn.com - April 12 at 7:32 AM
Oncocyte announces $15.8 mln private placement of securitiesOncocyte announces $15.8 mln private placement of securities
msn.com - April 12 at 7:32 AM
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTSONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS
prismmediawire.com - April 12 at 6:00 AM
Oncocyte Reports Full Year 2023 Financial ResultsOncocyte Reports Full Year 2023 Financial Results
globenewswire.com - April 12 at 6:00 AM
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
prismmediawire.com - April 11 at 9:48 PM
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
globenewswire.com - April 11 at 9:46 PM
Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayOncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
globenewswire.com - April 11 at 5:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ayala Pharmaceuticals logo

Ayala Pharmaceuticals

NASDAQ:AYLA
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Lyra Therapeutics logo

Lyra Therapeutics

NASDAQ:LYRA
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
OncoCyte logo

OncoCyte

NASDAQ:OCX
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.